Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

Australia

Austria

Belgium

Brazil *

Canada

China *

Denmark

Finland

France

Germany

Hong Kong *

India *

Ireland

Italy

Japan *

Luxembourg

Mexico *

Netherlands

Norway

Philippines *

Republic of Korea *

Singapore *

Spain

Sweden

Switzerland

Thailand *

United Kingdom

United States

HTRF Human VHL Binding Kit, 500 Assay Points

The VHL binding assay is designed to screen and characterize compounds that specifically bind to the E3 ligase, VHL.

View product information

Feature	Specification
Application	Protein-Protein Interaction
Sample Volume	5 µL

Request More Information

The VHL binding assay is designed to screen and characterize compounds that specifically bind to the E3 ligase, VHL.

View product information

Product Variants

Part #:

64BDVHLPEG

List Price

USD 1,304.58

Part #:

64BDVHLPEH

List Price

USD 15,640.42

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Product information

Overview

A fast and easy way to identify new binders to VHL protein.

VHL, also known as von Hippel-Lindau, is involved in many biological processes and is closely associated with the regulation of angiogenesis, cell growth, or cell survival.

VHL is one of the most popular E3 ligases recruited by bifunctional Proteolysis-targeting chimeras (PROTACs) to induce ubiquitination and subsequent proteasomal degradation of a targeted protein.

VHL interacts with several proteins to form the functional von Hippel-Lindau ubiquitination complex, in which VHL seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex, and targets various proteins to proteolysis such as the hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions.

Therefore, identifying new PROTAC VHL ligands can improve selective proteasomal-dependent degradation of proteins of interest, involved in the onset of diseases such as cancers.

Specifications

Other Specifications

Application	Protein-Protein Interaction
Automation Compatible	Yes
Brand	HTRF
Detection Modality	HTRF
Product Group	Kit
Sample Volume	5 µL
Shipping Conditions	Shipped in Dry Ice
Target Class	Binding Assay
Target Species	Human
Technology	TR-FRET
Therapeutic Area	Inflammation Neuroscience Oncology & Inflammation
Unit Size	500 Assay Points

Video gallery

How it works

Assay principle

The HTRF Human VHL Binding Kit is a competitive assay format which uses a VHL-Red Ligand as VHL ligand, a 6His-tagged human VHL protein complex, and an anti 6His Europium Cryptate-labeled antibody. VHL binding compounds compete with the VHL-Red Ligand and thereby prevent FRET from occurring.

Assay protocol

The VHL binding assay can be run in a 96- or 384-well low volume white plate (20 µL final). As described here, samples or standards are dispensed directly into the assay plate. The 6His-tagged VHL protein complex is then added, followed by the dispensing of the HTRF reagents: The anti 6His antibody labeled with Europium cryptate and the VHL Ligand labeled with a Red HTRF acceptor. The reagents labeled with HTRF fluorophores may be pre-mixed and added in a single dispensing step. No washing steps are needed. The protocol can be further miniaturized or upscaled by simply resizing each addition volume proportionally.

Assay validation

Screening of VHL orthosteric ligands

Two VHL ligands were characterized.

VH-032 (assay standard) and VH-298 display the expected potencies in good correlation with the literature. An irrelevant compound Lenalidomide (Cereblon ligand) does not compete with the VHL-Red Ligand binding, demonstrating the specificity of the HTRF VHL Binding Kit.

Screening of PROTAC compounds (VHL-ligand based)

Four VHL-ligand based PROTAC compounds (CRBN-6-5-5-VHL, TBK1 , CM 11 and ARV-771) were characterized. All compounds display the right pharmacological ranking in good correlation with the literature.

DMSO effect on assay performance

Different percentages of DMSO were tested, from 0.1% to 2% (final in the wells). The results indicate that the assay window is reduced with the increasing percentages of DMSO, while the pharmacology remains stable.